Icon

Vivitrol - (380 mg/vial; Extended-release Injectable Suspensio)

Naltrexone Alkermes
380 mg/vial; Extended-release Injectable Suspensio
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
Less Than 5
None
VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.
Yes
**** ** ***. **** ***** * **** ** ** ****** '*** *** *** *********. ** ****** **** **** **** ****** ** ***** ****. ********* ** ******** *** ******, ** ***** ** ******* ** *** ********** ** ****** **** *** ****, ** **** **** **** ****** *************** *** (“******”), ********* ******* ****** * ***-********* ******* ***** ******* ******* ******** ********, ********* *** ********* ****** ******** ******** ** *** *.*., ** ****** *** **** * ******* *********** ** ******** ** *** *.*. ********* ******** ** **** ** ******* ***** ******************.** (*****://********.********.***/******-*****/********-****-****-****-************)
Vivitrol Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7
**** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *******
****** ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* ***** *, **** ******* ******** ** *** **, ****
****** ** \ ** -**- ******* **** ** ** ****
  1. *** **, **** : **** ** ***** ** **** *******, *** ********* **** *** *******.
  2. *** **, **** : **** ******** ******* ***** **'* **** ** ****** ** ****** '***
  3. *** *, **** : ******** ***** * **** ******* **** ** ****** '***
  4. *** **, **** : ****** ***** * ******** ** **** **** ***** ****** ****** ** ********** *** ****** *-** ** *** ’*** ******,
  5. *** **, **** : ** ***** ** ******* ** *** ********** ** ****** **** *** ****, ******** ******* ****** * ***-********* ******* ***** ******* ******* ******** ********, ********* *** ********* ****** ******** ******** ** *** *.*., ** ****** *** **** * ******* *********** ** ******** ** *** *.*. ********* ******** ** **** ** ******* ***** ******************.
  6. *** **, **** : **** ****** **** *** **** ******* ********* ****** '***. **** ** ** ****** ***** ***/** ***********, **** ***** *** ** **** ** ****** ****** *** ****.
  7. *** **, **** : ******** *** **** ******* **********, ********* ** ***** **** *** ****** ***** ******* **** *** **, ****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.